logo
OSU's silence continues while its Faculty Council expresses thanks for Kayse Shrum's tenure

OSU's silence continues while its Faculty Council expresses thanks for Kayse Shrum's tenure

Yahoo06-02-2025

A lot of people connected with Oklahoma State University liked now-former OSU President Kayse Shrum and have been vocal in saying so since her sudden resignation became publicly known on Tuesday.
But even as the university, and the OSU/A&M Board of Regents, maintains radio silence about the 'why' behind Shrum's departure after less than four years in office, it's clear Shrum wasn't so chummy with members of the nine-person regents board that oversees the university. The internal conflict, according to multiple media reports, boiled over last Friday during a regular meeting of the board.
Documents obtained by online news agency NonDoc appear to show four motions approved by regents during the meeting, after a long executive session concerning a review of the OSU Innovation Foundation, a favored project of Shrum which was rebranded in 2023 from its former name, the Oklahoma State University Research Foundation. Shrum said then the foundation was 'a crucial pillar of our We Are Land-Grant strategy' she forged during her tenure.
The NonDoc report indicated regents were reviewing transfers of funds appropriated by the Legislature involving OSU's Innovation Foundation, something The Oklahoman has been unable to confirm. The Oklahoman did confirm one of the Innovation Foundation's executives, Elizabeth Pollard, has resigned.
Another person whose resignation from OSU was confirmed was Jerome Loughridge. Loughridge, though, said in an email to The Oklahoman Thursday that contrary to earlier reports listing him as an executive with the Innovation Foundation, he left the foundation in March 2023 to serve as Shrum's chief of staff. He said he was leaving OSU to work at a nonprofit based in Washington, D.C., and that his departure from OSU had been communicated in January. Loughridge said he was working his last days in his role at OSU 'per common practice' and emphasized he did not resign with Pollard.
According to its website, the Innovation Foundation's mission 'is to maximize the impact of OSU's excellence in aerospace and advanced mobility, energy, agriculture, and One Health by translating innovative applied research into products and services, facilitating strong partnerships with aligned industry and regional partners, and investing in the development of emerging companies — all for the benefit of society.'
Be the first to know: Sign up for breaking news email alerts
Minutes from the Dec. 31 meeting haven't yet been approved by the regents, and so they were not available for public review. The regents have scheduled a special meeting for this Friday morning in Stillwater, at which they'll hold 'Discussions regarding an interim appointment to fill the position of President of Oklahoma State University and the OSU System,' according to the posted agenda.
Jeannette Mendez, OSU's current provost and senior vice president, is serving as acting president until an interim president is named. She's worked at OSU since 2005.
Shrum hasn't returned messages left by The Oklahoman and other than a short statement that didn't reveal any rationale behind what happened, the regents haven't spoken either. Normally cooperative OSU officials also have failed to return messages in recent days.
The OSU/A&M regents board works under the umbrella of the Oklahoma State Regents for Higher Education, an executive agency that oversees all public colleges and universities in the state. Such was OSU's wall of silence that the state's top education official, Chancellor Sean Burrage, said he didn't become aware of Shrum's pending resignation until media reports emerged Tuesday night.
Similarly, the chair of the state regents' board, Dennis Casey of Morrison, told The Oklahoman he never heard from his counterpart on the OSU board, Jimmy Harrel, who's served on both the OSU and state regents boards on and off since the 1990s.
Multiple state legislators issued statements Wednesday, all praising Shrum for her work as president. On Thursday, the OSU Faculty Council joined them, expressing its appreciation for 'her leadership style that valued academic input and shared governance. During her presidency, Dr. Shrum maintained regular dialogue with the Faculty Council, demonstrating a willingness to engage with and respond to faculty concerns. Her support of faculty initiatives and her understanding of the challenges facing higher education helped strengthen the relationship between administration and faculty. Through regular meetings with the Faculty Council and various faculty committees, she fostered an environment where faculty voices were heard and respected.'
The statement was signed by the council's officers, including its chair, Lisa Slevitch, a professor in the university's hotel and restaurant administration program. It said the council 'will closely monitor the upcoming leadership transition process' and is 'committed to representing faculty interests and ensuring that academic values remain central to university decisions.'
OSU's women's basketball coach Jacie Hoyt was emotional when speaking about Shrum, who approved Hoyt's hire.
"For Jacie Hoyt, she meant a lot. She does mean a lot," Hoyt said. "She's been an incredible friend to me. She's been an incredible mentor. She's someone that I look up to as a female leader. She's everything that I hope I can be. She's got wisdom. She's got class. She's got integrity. She's just a leader. She's been with me through the highest of highs in my time here and the lowest of lows. ... I feel like I kind of lost a hero in that sense."
House Speaker Kyle Hilbert, R-Bristow, said Thursday he'd been on OSU's campus as recently as a week ago Thursday and that he had no inkling of what was brewing. He said he first heard of Shrum's resignation Tuesday morning.
'We'll see, as things come out, what the reasoning was,' Hilbert said. 'I think there's a lot of speculation, but until more facts come to light, we'll see. We'll continue to have conversations with the OSU/A&M regents about everything and whatever happened.
'Clearly, something happened. That's not a secret. … We as a Legislature, we'll dig into it. Those were state funds that were appropriated and we don't know.'
Hilbert was asked about what level of transparency he expected from the OSU/A&M regents. He said once the interim president is selected, he's told the regents he wants to meet with that person 'to have those conversations about, you need to come to the Legislature and talk about what did or didn't happen, so we can be fully aware of it.'
Hilbert mentioned OSU had made multiple large financial requests of the Legislature this year and that before lawmakers considered those, they would want to know what happened with money appropriated after previous requests.
This article originally appeared on Oklahoman: OSU faculty, coach join praise for Kayse Shrum after her resignation

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

American Water to Provide Expertise at 2025 SEARUC Annual Education Conference
American Water to Provide Expertise at 2025 SEARUC Annual Education Conference

Business Wire

time4 hours ago

  • Business Wire

American Water to Provide Expertise at 2025 SEARUC Annual Education Conference

BUSINESS WIRE)-- American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., is participating in the 2025 Southeastern Association of Regulatory Utility Commissioners (SEARUC) Annual Education Conference, taking place June 8 through June 11, 2025, in San Antonio, Texas. The event brings together commissions, utility leaders and industry experts from across the Southeast to explore emerging regulatory issues and share best practices. 'Investing in our systems today is more than pipes and plants—it's about helping ensure reliable service, protecting public health and building resilient communities," said Grant Evitts, President of Tennessee American Water. Grant Evitts, President of Tennessee American Water, spoke today as part of the panel discussion Dollars for Drops: Investing in Water Infrastructure. The session will focus on the critical need for sustainable investment in aging infrastructure and how public-private partnerships, thoughtful regulation and innovation can help ensure safe, reliable service for generations to come. 'Grant's participation in such a critical panel underscores our commitment to resilient and sustainable infrastructure investment and our belief in working with regulators to meet the evolving needs of the communities we serve,' said Cheryl Norton, EVP and Chief Operating Officer, American Water. 'We're proud to see Grant advancing these fundamental conversations across the Southeast.' 'It's an honor to join industry peers and regulators at SEARUC to discuss the future of water infrastructure in our region,' said Evitts. 'Investing in our systems today is more than pipes and plants—it's about helping ensure reliable service, protecting public health and building resilient communities. I'm proud to represent our team and share how collaboration and innovation are helping us deliver long-term value to customers.' With operations across multiple southeastern states, American Water plays a vital role in addressing region-specific infrastructure needs while advancing sustainable, customer-focused solutions. Through leadership participation in SEARUC, the company continues to engage in meaningful dialogue with regulators and industry partners to strengthen utility performance and public trust. For more information about the SEARUC 2025 Annual Conference, visit About American Water American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. American Water's 6,700 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders.

American Water to Provide Expertise at 2025 SEARUC Annual Education Conference
American Water to Provide Expertise at 2025 SEARUC Annual Education Conference

Yahoo

time4 hours ago

  • Yahoo

American Water to Provide Expertise at 2025 SEARUC Annual Education Conference

CAMDEN, N.J., June 10, 2025--(BUSINESS WIRE)--American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., is participating in the 2025 Southeastern Association of Regulatory Utility Commissioners (SEARUC) Annual Education Conference, taking place June 8 through June 11, 2025, in San Antonio, Texas. The event brings together commissions, utility leaders and industry experts from across the Southeast to explore emerging regulatory issues and share best practices. Grant Evitts, President of Tennessee American Water, spoke today as part of the panel discussion Dollars for Drops: Investing in Water Infrastructure. The session will focus on the critical need for sustainable investment in aging infrastructure and how public-private partnerships, thoughtful regulation and innovation can help ensure safe, reliable service for generations to come. "Grant's participation in such a critical panel underscores our commitment to resilient and sustainable infrastructure investment and our belief in working with regulators to meet the evolving needs of the communities we serve," said Cheryl Norton, EVP and Chief Operating Officer, American Water. "We're proud to see Grant advancing these fundamental conversations across the Southeast." "It's an honor to join industry peers and regulators at SEARUC to discuss the future of water infrastructure in our region," said Evitts. "Investing in our systems today is more than pipes and plants—it's about helping ensure reliable service, protecting public health and building resilient communities. I'm proud to represent our team and share how collaboration and innovation are helping us deliver long-term value to customers." With operations across multiple southeastern states, American Water plays a vital role in addressing region-specific infrastructure needs while advancing sustainable, customer-focused solutions. Through leadership participation in SEARUC, the company continues to engage in meaningful dialogue with regulators and industry partners to strengthen utility performance and public trust. For more information about the SEARUC 2025 Annual Conference, visit About American WaterAmerican Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. American Water's 6,700 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders. For more information, visit and join American Water on LinkedIn, Facebook, X and Instagram. View source version on Contacts Media Contact: Alicia BarbieriDirector, Corporate Communications and External AffairsAmerican Water(856) Sign in to access your portfolio

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

Yahoo

time8 hours ago

  • Yahoo

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. "The blood cancer burden on India's population is substantial, around 120,000 new cases of lymphoma, leukemia, and multiple myeloma are diagnosed each year. Unfortunately, almost 70,000 Indians will die every year from these afflictions, devastating the lives of their families and communities. To afford access to all Indian patients in need, and to capitalize on the immense commercial potential of our pipeline, we need to think prudently and practically about our manufacturing approach. In the short term, our manufacturing demands are almost 200 drug products per day, and this may increase as CAR-T cell therapies move closer to front line treatment. The only practical way for us to industrialize our production and produce a supply of drug product commensurate with total patient demand is to transition to G-Rex," said Dr. Lakshmikanth Gandikota, Head of R&D, MSAT Intellectual Property, and Translational Research, at Immuneel Therapeutics Limited. "We are extremely impressed by the speed, resourcefulness, creativity, discipline, and entrepreneurialism of the team at Immuneel and are happy to see that India, as a whole, is making significant strides toward CAR-T availability. It gives us a great sense of satisfaction to be in a position to help bring hope to cancer patients in India, one G-Rex at a time," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of Immuneel's G-Rex Grant, they will perform process development, qualification, and validation of a G-Rex based CAR-T cell therapy production approach to dramatically increase the throughput capacity of their state-of-the-art, 12,000 square foot GMP facility. Located in Bengaluru and opened in 2021, Immuneel's Integrated Cell Therapy Development and Manufacturing Facility was the first of its kind in India and is designed to bring breakthrough cell and gene therapies to millions of patients in India. Lastly, Immuneel's G-Rex Grant will support the requisite comparability studies necessary to support a post-CAR-T approval manufacturing change from their difficult to scale low throughput all-in-one manufacturing equipment to a much simpler high throughput G-Rex centric approach. The high popularity of ScaleReady's G-Rex Grant Program led ScaleReady to increase award funds from the original amount of $20M to a total of $30M directed towards saving recipients significant time and money by expediting the path to optimized cell and gene-modified cell therapy manufacturing. Two hundred grants have already been awarded with over 50 new applications in the queue. Each G-Rex Grant recipient can obtain up to $300,000 and gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. For more information about the G-Rex® Grant Program, please contact info@ About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Immuneel therapeutics Private LimitedImmuneel Therapeutics Private Limited is a cutting-edge biotechnology company based in Bangalore, India, at the forefront of advancing cell and gene therapies, as well as personalized immunotherapies, for cancer patients in India. As a research-driven and fully integrated organization, Immuneel is dedicated to making next-generation cancer treatments accessible and affordable, with a strong focus on innovation and clinical impact. The company's mission is to democratize advanced therapies by developing and commercializing breakthrough solutions tailored to the needs of Indian patients. As part of its growing portfolio, Immuneel has licensed and commercialized Qartemi® (varnimcabtagene autoleucel), a CD19 CAR-T cell therapy approved by India's Central Drugs Standard Control Organization (CDSCO) for the treatment of adult B-cell non-Hodgkin lymphoma a novel therapy for blood cancer, further demonstrating its commitment to transforming cancer care in India. Immuneel has a robust pipeline of CAR-T therapies for various indications in Oncology and AutoImmune diseases For more information, please visit: View original content to download multimedia: SOURCE Bio-Techne Corporation

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store